$232.23 Million in Sales Expected for Prestige Consumer Healthcare Inc (PBH) This Quarter

Analysts forecast that Prestige Consumer Healthcare Inc (NYSE:PBH) will announce sales of $232.23 million for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Prestige Consumer Healthcare’s earnings, with the lowest sales estimate coming in at $230.80 million and the highest estimate coming in at $234.70 million. Prestige Consumer Healthcare reported sales of $253.98 million during the same quarter last year, which indicates a negative year-over-year growth rate of 8.6%. The business is expected to announce its next quarterly earnings report on Thursday, August 1st.

According to Zacks, analysts expect that Prestige Consumer Healthcare will report full year sales of $954.88 million for the current fiscal year, with estimates ranging from $954.00 million to $955.90 million. For the next year, analysts anticipate that the firm will post sales of $964.10 million, with estimates ranging from $963.50 million to $964.60 million. Zacks’ sales calculations are an average based on a survey of research analysts that follow Prestige Consumer Healthcare.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Thursday, May 9th. The company reported $0.72 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.70 by $0.02. Prestige Consumer Healthcare had a negative net margin of 3.67% and a positive return on equity of 12.45%. The company had revenue of $241.03 million for the quarter, compared to analyst estimates of $237.22 million. During the same quarter in the prior year, the business posted $0.62 EPS. The firm’s revenue was down 5.8% compared to the same quarter last year.

PBH has been the topic of a number of analyst reports. TheStreet lowered shares of Prestige Consumer Healthcare from a “c” rating to a “d+” rating in a report on Friday, May 10th. Zacks Investment Research lowered shares of Prestige Consumer Healthcare from a “hold” rating to a “sell” rating in a report on Friday, February 1st. Desjardins lowered shares of Prestige Consumer Healthcare to a “hold” rating and set a $88.00 target price on the stock. in a report on Wednesday, February 13th. Royal Bank of Canada reiterated a “buy” rating and issued a $97.00 price objective on shares of Prestige Consumer Healthcare in a research note on Friday, March 15th. Finally, ValuEngine upgraded shares of Prestige Consumer Healthcare from a “strong sell” rating to a “sell” rating in a research note on Monday, April 29th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $54.07.

PBH opened at $30.28 on Wednesday. The company has a current ratio of 2.37, a quick ratio of 1.43 and a debt-to-equity ratio of 1.64. Prestige Consumer Healthcare has a fifty-two week low of $26.25 and a fifty-two week high of $41.76. The stock has a market capitalization of $1.54 billion, a P/E ratio of 10.89, a price-to-earnings-growth ratio of 1.71 and a beta of 0.96.

Large investors have recently bought and sold shares of the business. Premia Global Advisors LLC purchased a new stake in Prestige Consumer Healthcare in the 1st quarter valued at about $26,000. First Hawaiian Bank increased its stake in Prestige Consumer Healthcare by 218.4% in the 4th quarter. First Hawaiian Bank now owns 1,210 shares of the company’s stock valued at $37,000 after buying an additional 830 shares during the last quarter. FNY Investment Advisers LLC purchased a new stake in Prestige Consumer Healthcare in the 4th quarter valued at about $37,000. Financial Gravity Wealth Inc. purchased a new stake in Prestige Consumer Healthcare in the 1st quarter valued at about $50,000. Finally, Quadrant Capital Group LLC increased its stake in Prestige Consumer Healthcare by 2,979.3% in the 1st quarter. Quadrant Capital Group LLC now owns 1,786 shares of the company’s stock valued at $53,000 after buying an additional 1,728 shares during the last quarter.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) healthcare and household cleaning products in North America, Australia, and internationally. It operates in three segments: North American OTC Healthcare, International OTC Healthcare, and Household Cleaning.

See Also: Diversification Important in Investing

Get a free copy of the Zacks research report on Prestige Consumer Healthcare (PBH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Prestige Consumer Healthcare (NYSE:PBH)

Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.